Patient dies in MacroGenics' cancer study, FDA puts trial on hold

Max Gelman / endpoints - The FDA has placed a partial clinical hold on MacroGenics’ Phase 2 study in gynecologic cancers after one patient died and three others experienced life-threatening side effects, the company disclosed Tuesday. The patient who died ...

AI Summary: Regulators have imposed a partial hold on a Phase 2 gynecologic cancer trial after multiple serious adverse events, including one patient death and additional safety incidents. The pause mandates review of trial protocols and safety monitoring before enrollment can resume, highlighting the inherent risks when experimental therapies meet human biology.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Boehringer gains fast approval for first‑line lung cancer drug via voucher program / 3 months

Cancer Research UK campaign clears £250M milestone for research / 3 months

Household cats reveal human cancer gene parallels and treatment clues / 3 months

FDA Lifts Hold on Intellia’s Phase 3 Gene Editing Trial / 4 months

FDA rejects Corcept’s cortisol modulator triggering setback / 4 months

FDA approves Rucaparib for advanced prostate cancer / 5 months

FDA approves first gene therapy for Wiskott‐Aldrich syndrome / 5 months